Abstract B13: Pilot trial of gemcitabine, nab-paclitaxel, metformin, and a standardized dietary supplement in patients with unresectable pancreatic cancer

Background: Dietary supplement use has increased over the last decade, and the prevalence is estimated to be 76% of the adult US population as reported by the Council for Responsible Nutrition. However, consistent regular use has only been reported in about 33% of subjects. Pancreatic cancer patients commonly present with weight loss and seek out supplements to improve nutrition but also for any potential anticancer properties that may exist. We...